Although the ELISA results indicated that the treatment did not affect IFN-γ secretion in MG patients, the flow cytometry results confirmed that it reduced IFN-γ secretion in responsive patients by inhibiting Th1 cells. The gene discussed is IFNG; the disease is myasthenia gravis.